TAS::75 0849::TAS; SBIR TOPIC 255, PHASE II "A STRADOBODY DIRECTED AGAINST LOW E

塔斯马尼亚州::75 0849::塔斯马尼亚州；

基本信息

批准号：
8351825
负责人：
HENRIK OLSEN
金额：
$ 150万
依托单位：
GLIKNIK, INC.
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-29 至 2013-09-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8351825
关键词：
Antibodies Antigens Antineoplastic Agents Binding Cell Line Cells Clinical Clinical Trials Commit Contractor Contracts Data Development Disulfides Drug Kinetics ERBB2 gene Equipment and Supplies Funding Gel Gel Chromatography Gene Targeting Generations Genetic Polymorphism Genomics Genotype Government Half-Life Human Human Activities IgG Receptors Immune Indolent Investments Kinetics Lead Learning Licensing Lymphoma MS4A1 gene Malignant Neoplasms Marketing Measurement Measures Medical Methods Monitor Monoclonal Antibodies Mus Patients Peptide Mapping Phase Polishes Population Process Production Proteomics Quality Control Recurrence Relative (related person)Resistance Roche brand of rituximab Roche brand of trastuzumab Screening procedure Services Silver Staining Small Business Innovation Research Grant Specific qualifier value Structure-Activity Relationship System Time TimeLine Transfection Trastuzumab Tumor Cell Line Work antibody-dependent cell cytotoxicity base cell bank crosslink design glycosylation improved in vivo innovation malignant breast neoplasm neoplastic cell novel novel therapeutic intervention preclinical study process optimization response rituximab stable cell line therapeutic target tumor tumor growth vector

项目摘要

Background Information ¿ Rituxan¿ and Herceptin¿ are multi-billion dollar products that are useful in lymphoma and breast cancer. However, significant unmet medical need persists for certain populations such as recurrent indolent NHL, HER2 IHC 2+ patients, and treatment of patients with the FcgR3a 158 F/F polymorphism. This contract proposal is designed to: a) generate a novel anti-CD20 or anti-HER2 neu compound that will advance towards clinical trial and prove to have advantages over the currently marketed antibody compound, and b) establish a new therapeutic approach to cancer.

背景信息 ¿利妥昔单抗和赫赛汀??是价值数十亿美元的产品，可用于淋巴瘤和乳腺癌。然而，对于某些人群，例如复发性惰性 NHL、HER2 IHC 2+ 患者以及 FcgR3a 158 F/F 多态性患者的治疗，仍然存在大量未满足的医疗需求。该合同提案旨在：a) 产生一种新型抗 CD20 或抗 HER2 neu 化合物，该化合物将进入临床试验并证明比目前市售的抗体化合物具有优势，以及b) 建立一种新的癌症治疗方法。